Literature DB >> 6430316

Effect of valproate on free plasma phenytoin concentrations.

L M Tsanaclis, J Allen, E Perucca, P A Routledge, A Richens.   

Abstract

The plasma protein binding of phenytoin was studied in nine epileptic patients before and during addition of sodium valproate to the drug therapy. The free phenytoin fraction in plasma was significantly greater during sodium valproate treatment. The mean free fraction rose from 0.135 +/- 0.019 (s.d.) to 0.182 +/- 0.030. Total plasma phenytoin concentration fell significantly from a range of 4.3-26.2 micrograms/ml to 3.4-19.8 micrograms/ml during sodium valproate treatment. Neither the free plasma concentration nor the saliva concentration of phenytoin was significantly altered by sodium valproate. No significant correlation was found between plasma valproic acid concentrations and the change in phenytoin binding. We conclude that valproic acid displaces phenytoin from plasma protein binding sites but does not inhibit its metabolism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430316      PMCID: PMC1463568          DOI: 10.1111/j.1365-2125.1984.tb05015.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Rapid quantitation of N-dipropylacetamide in human plasma by gas-liquid chromatography.

Authors:  F Pisani; R Di Perri; G Nistico
Journal:  J Chromatogr       Date:  1979-06-01

2.  Quantitative estimation of diphenylhydantoin, primidone and phenobarbital in plasma by gas-liquid chromatography.

Authors:  H J Kupferberg
Journal:  Clin Chim Acta       Date:  1970-08       Impact factor: 3.786

3.  Albumin standards and the measurement of serum albumin with bromcresol green.

Authors:  B T Doumas; W A Watson; H G Biggs
Journal:  Clin Chim Acta       Date:  1971-01       Impact factor: 3.786

4.  Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients.

Authors:  A Monks; A Richens
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

5.  Stupor following administration of valproic acid to patients receiving other antiepileptic drugs.

Authors:  J C Sackellares; S I Lee; F E Dreifuss
Journal:  Epilepsia       Date:  1979-12       Impact factor: 5.864

6.  Valproic acid in epilepsy: clinical and pharmacological effects.

Authors:  R H Mattson; J A Cramer; P D Williamson; R A Novelly
Journal:  Ann Neurol       Date:  1978-01       Impact factor: 10.422

7.  Plasma protein binding interaction between phenytoin and valproic acid in vitro.

Authors:  A Monks; S Boobis; J Wadsworth; A Richens
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

8.  Decreased plasma protein binding of phenytoin in patients on valproic acid.

Authors:  R Dahlqvist; O Borgå; A Rane; Z Walsh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

9.  Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects.

Authors:  E Perucca; S Hebdige; G M Frigo; G Gatti; S Lecchini; A Crema
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

10.  Interactions of valproic acid with phenytoin.

Authors:  J Bruni; J M Gallo; C S Lee; R J Perchalski; B J Wilder
Journal:  Neurology       Date:  1980-11       Impact factor: 9.910

View more
  7 in total

Review 1.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 2.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

3.  Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.

Authors:  G J Johnson; C J Kilpatrick; R W Bury; R O Fullinfaw; R F Moulds
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

4.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

Review 5.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 6.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 7.  Clinically relevant drug interactions with antiepileptic drugs.

Authors:  Emilio Perucca
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.